These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16120628)

  • 1. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis.
    Zeitlinger MA; Erovic BM; Sauermann R; Georgopoulos A; Müller M; Joukhadar C
    J Antimicrob Chemother; 2005 Oct; 56(4):703-8. PubMed ID: 16120628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
    Frei CR; Burgess DS
    Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model.
    Sauermann R; Zeitlinger M; Erovic BM; Marsik C; Georgopoulos A; Müller M; Brunner M; Joukhadar C
    Int J Antimicrob Agents; 2003 Dec; 22(6):574-8. PubMed ID: 14659654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement.
    Dalley AJ; Lipman J; Venkatesh B; Rudd M; Roberts MS; Cross SE
    J Antimicrob Chemother; 2007 Jul; 60(1):166-9. PubMed ID: 17504805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models.
    Giacometti A; Ghiselli R; Cirioni O; Mocchegiani F; D'Amato G; Orlando F; Sisti V; Kamysz W; Silvestri C; Naldoski P; Lukasiak J; Saba V; Scalise G
    J Antimicrob Chemother; 2004 Sep; 54(3):654-60. PubMed ID: 15294887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome.
    Sádaba B; Azanza JR; Campanero MA; García-Quetglas E
    Clin Microbiol Infect; 2004 Nov; 10(11):990-8. PubMed ID: 15522002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock.
    Joukhadar C; Frossard M; Mayer BX; Brunner M; Klein N; Siostrzonek P; Eichler HG; Müller M
    Crit Care Med; 2001 Feb; 29(2):385-91. PubMed ID: 11246321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is aztreonam could become "a challenger" for treatment of Gram negative infections? May be an answer from microbiological data: in vitro study including 36,485 strains of enterobacteria and Pseudomonas].
    Honderlick P; Gravisse J; Dardelle D; Cahen P
    Pathol Biol (Paris); 2007 Dec; 55(10):475-7. PubMed ID: 17904768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PK-PD modeling of β-lactam antibiotics: in vitro or in vivo models?
    de Araujo BV; Diniz A; Palma EC; Buffé C; Dalla Costa T
    J Antibiot (Tokyo); 2011 Jun; 64(6):439-46. PubMed ID: 21505469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
    Xiao XM; Xiao YH
    Acta Pharmacol Sin; 2008 Oct; 29(10):1253-60. PubMed ID: 18817632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetic and pharmacodynamic activity of piperacillin and mezlocillin.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney K
    Pharmacotherapy; 1993; 13(6):607-12. PubMed ID: 8302686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.